847555-74-2

Upstream product

• 591-51-5 phenyllithium 
• 17532-20-6 diphenyl(piperazin-2-yl)methanol 
• 17532-22-8 (1,4-dibenzyl-piperazin-2-yl)-diphenyl-methanol 
• 132740-43-3 4-fluorobenzylisocyanate 
• 847555-93-5 1,1-diphenyltetrahydro-1H-oxazolo[3,4-α]pyrazin-3(5H)-one 
• 1287264-25-8 {2-[(2-chloroacetyl)-(1-phenylethyl)amino]ethyl}carbamic acid tert-butyl ester 
• 1287264-32-7 (R)-1,1-diphenyl-7-((S)-1-phenylethyl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 
• 1287264-33-8 3-oxo-1,1-diphenyltetrahydrooxazolo[ 3,4-a]pyrazine-7-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 944256-02-4 4-(1-phenylethyl)piperazine carboxylic acid tert-butyl ester 
• 1287264-28-1 3-oxo-4-(1-phenylethyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Identification of neuropeptide s antagonists: Structure-Activity relationship studies, x-ray crystallography, and in vivo evaluation

Modulation of the neuropeptide S (NPS) system has been linked to a variety of CNS disorders such as panic disorder, anxiety, sleeping disorders, asthma, obesity, PTSD, and substance abuse. In this study, a series of diphenyltetrahydro-1H-oxazolo[3,4-α]pyr

Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9 R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4- a ]pyrazine-7-carboxylic Acid 4-fluoro-benzylamide (SHA 68)

This study reports the synthesis, chromatographic separation, and pharmacological evaluation of the two enantiomers of the neuropeptide S receptor (NPSR) antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine- 7-carboxylic acid 4-fluoro-be